PDGFRB and colorectal carcinoma: In a CRC mouse model, the combination of PDGFR inhibitor Dasatinib and anti-programmed cell death-1 (PD-1) antibody has been shown to suppress CAF proliferation, promote immune cell infiltration, activate anti-tumor immunity, and induce tumor regression [65].